Top Medical News
9 hours ago
Once-weekly treatment with carfilzomib at the higher 70-mg/m2 dose appears to improve survival in patients with relapsed and refractory multiple myeloma (RRMM) compared with the twice-weekly 27-mg/m2 dosing regimen, regardless of patient and disease characteristics, according to data from the phase III ARROW study.
10 hours ago
Low preoperative prognostic nutritional index (PNI) has a significant impact on the completion of planned adjuvant chemotherapy (AC) following curative resection of stage II/III gastric cancer, a study has shown. Low PNI and incomplete AC confer an additive effect and lead to worse outcomes.
Stephen Padilla, 11 hours ago
Use of proton-pump inhibitors (PPIs) for ≥2 years is not associated with a higher risk of gastrointestinal cancers, while the association of PPI use of ≥10 years with cancer risk remains unclear, reveals a study.
Pearl Toh, Yesterday
Patients with any subtypes of polyps had a greater risk of developing colorectal cancer (CRC) than the general population in a largely screening-naive Swedish cohort, indicating that CRC risk is not limited to just those with advanced histology, reveals a large registry-based study.
The rate of polypharmacy is high among patients with multiple myeloma, according to a study. However, comanagement with a pharmacist reduces the number of all medications, particularly those that are not related to myeloma.
2 days ago
MuGard and Caphosol do not appear to be more effective than standard topical therapy at reducing pain scores or increasing mucosal recovery in the treatment of chemotherapy-induced oral mucositis, a recent study has shown.
Jairia Dela Cruz, 2 days ago
Liquid biopsy may facilitate detection and serial monitoring of multidrug resistance (MDR) in multiple myeloma by analysing multiparticles (MPs) in blood samples of patients, with a recent study showing that MDR markers are found on MPs of stem-cell-like origin.
Special Reports
13 Feb ck棋牌
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM. 
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

14 Aug 2019
Renal cell carcinoma (RCC) is the most common primary tumour arising from the kidney, constituting approximately 80–85% of primary renal neoplasms. According to the Malaysian National Cancer Registry Report 2007–2011, RCC accounts for 62.8% of all kidney cancers nationwide. RCC typically occurs approximately 50% more commonly in men compared with women, and predominantly occurs in the sixth to eighth decade of life.
30 Jan 2019
In March 2018, sublingual fentanyl citrate (SLF; Abstral®, Menarini) was made available in Malaysia. SLF is a rapid-onset opioid (ROO) indicated for the management of breakthrough cancer pain (BTcP) episodes in patients that are opioid-tolerant. In July 2018, Menarini organized an expert meeting, aptly named Malaysian Collaborative Meeting of Pain Specialists to Improve Oncology Management (MY-COMPASSION), comprising of key figures in anaesthesiology, palliative care and oncology to discuss current insights into local BTcP management. Below are highlights from the meeting.
Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 24 Jan 2019
Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.
21 Nov 2018
Recently, a Roche-sponsored dinner symposium was held in conjunction with the launch of atezolizumab (Tecentriq®, Roche) at Royale Chulan, Kuala Lumpur. Important insights into the evolving treatment landscape of anticancer treatment, and the increasingly prominent role of immunotherapy were gathered from a distinguished panel, including Dato’ Dr Mohamed Ibrahim, Professor Dr Rolf A. Stahel, Dr Voon Pei Jye, and Associate Professor Dr Tho Lye Mun. Here are the highlights of the meeting.
Conference Reports
Pearl Toh, 30 Apr ck棋牌
Frontline maintenance treatment with a DNA engineered autologous tumour cell (EATC) immunotherapy yields relapse-free survival (RFS) benefit in patients with advanced epithelial ovarian cancer, particularly in those with wild-type BRCA1/2 status, according to the VITAL* study presented at the ck棋牌 SGO Annual Meeting.
Roshini Claire Anthony, 30 Apr ck棋牌

Young gynaecological cancer survivors have an increased risk of bone mineral density (BMD) reductions and osteoporosis, according to a study scheduled for presentation at SGO 20/20.

Roshini Claire Anthony, 27 Apr ck棋牌

Receipt of an adjuvant human papillomavirus (HPV) vaccine following surgical excision could reduce the risk of cervical intraepithelial neoplasia (CIN2+) recurrence, according to a systematic review and meta-analysis submitted for presentation at SGO 20/20.

Audrey Abella, 23 Mar ck棋牌
The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU ck棋牌. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
Elaine Soliven, 14 Mar ck棋牌
The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU ck棋牌.
Pearl Toh, 09 Mar ck棋牌
A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS ck棋牌.
Roshini Claire Anthony, 05 Mar ck棋牌

Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU ck棋牌.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download